Curated News
By: NewsRamp Editorial Staff
December 30, 2024
Securities Class Action Lawsuit Filed Against Applied Therapeutics, Inc. by Kessler Topaz Meltzer & Check, LLP
Discuss on Reddit
LinkedIn
Telegram
GithubTLDR
- Lead plaintiff deadline for securities class action lawsuit against Applied Therapeutics, Inc. is February 18, 2025, offering opportunity for investors.
- Defendants allegedly did not adhere to trial protocol for drug candidate govorestat, increasing risk of FDA rejection for trial data.
- Kessler Topaz Meltzer & Check, LLP aims to protect investors from fraud and negligence, seeking justice for victims of corporate misconduct.
- Investors who suffered losses due to misconduct by Applied Therapeutics, Inc. can seek legal recourse by becoming a lead plaintiff in the class action lawsuit.
Impact - Why it Matters
This news matters as it highlights potential misconduct by Applied Therapeutics, impacting investors who purchased securities during the specified period. Investors who suffered losses are encouraged to contact Kessler Topaz Meltzer & Check, LLP to seek information and potentially become a lead plaintiff representative of the class.
Summary
The law firm of Kessler Topaz Meltzer & Check, LLP has filed a securities class action lawsuit against Applied Therapeutics, Inc. on behalf of investors who purchased securities between January 3, 2024, and December 2, 2024. The lawsuit alleges that Applied Therapeutics did not adhere to trial protocol and good clinical practices for its drug candidate, govorestat, posing a risk of FDA rejection.
Source Statement
This curated news summary relied on this press release disributed by NewMediaWire. Read the source press release here, Securities Class Action Lawsuit Filed Against Applied Therapeutics, Inc. by Kessler Topaz Meltzer & Check, LLP
